EAST WINDSOR, N.J., Nov. 28, 2018 (GLOBE NEWSWIRE) -- Novitium Pharma LLC is pleased to announce that it has received U.S. Food and Drug Administration approval on its Abbreviated New Drug Application (“ANDA”) for Ranitidine Capsules 150 mg and 300 mg, and will be distributing product to customers. Ranitidine is a therapeutic equivalent to the reference listed drug Zantac® of GlaxoSmithKline PLC. For the 12 months ended October 2018, total U.S. sales of Ranitidine Capsules 150 mg and 300 mg was approximately $48 million according to IQVIA.
About Novitium Pharma
Novitium is a U.S. based pharmaceutical company that specializes in development, manufacturing, and distribution of niche generic pharmaceutical products. The company, founded in 2016, has since established a growing commercial product portfolio and developed a pipeline of over 20 ANDAs filed with the FDA, spanning a diverse range of dosage forms and therapeutic categories. Novitium continues to invest in producing affordable, high-quality medication to fulfill the needs of pharmacists, patients, and communities alike.
For more information about Novitium Pharma please visit www.novitiumpharma.com.